NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immunic, Inc. (IMUX) Stock Analysis

Immunic, Inc. (IMUX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMUX

$7.48

+$0.07 (+0.94%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMUX with… →

IMUX Key Statistics

As of Oct 21, 2026
Trading
Open
$7.44
Previous Close
$7.41
Day's Range
7.41–7.85
52-Week Range
5.06–17.43
Volume
329.58K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.45
Valuation
Market Cap
$102.06M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.83
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$97.17M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.64M
1-Year Return
−9.00%
Dividend and dates
Earnings Date
November 13, 2026
Avg Volume
312.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMUX closed at $7.48, −9.00% over 1 year.

Immunic, Inc. (IMUX) has a market capitalization of $102.06M.

In fiscal 2025, IMUX reported revenue of $0.00.

IMUX Stock Return by Calendar Year

Immunic, Inc. (IMUX) 10-year return: what $10,000 became

1 year
$10,000 $9,100
−9.00%
5 years
$10,000 $895
−91.05%
10 years
$10,000 $32
−99.68%

If you had invested $10,000 in Immunic, Inc. (IMUX) 10 years ago, at the close on October 21, 2016, it would have been worth $32 at the close on October 21, 2026: −99.68% in total, −43.71% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+40.07%
2025−46.60%
2024−33.33%
2023+7.14%
2022−85.37%
2021−37.41%
2020+57.63%
2019+30.38%
2018−96.87%
2017+36.78%
2016 (partial year)−27.50%

As of October 21, 2026.

IMUX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$97.17M—
2024$0.00−$100.51M—
2023$0.00−$93.61M—
2022$0.00−$120.41M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$103.23M−$97.17M—
2024$0.00—−$98.05M−$100.51M—
2023$0.00—−$99.22M−$93.61M—
2022$0.00—−$86.52M−$120.41M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immunic, Inc. (IMUX) is capitalised at $102.06M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 100 employees.

The 52-week range on file runs from $5.06 to $17.43. The most recent close on file for IMUX is $7.48, dated October 21, 2026. That is +$0.07 (+0.94%) against the previous close. The latest close sits 47.83% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $97.17M. Earnings per share on a trailing basis come to −3.83.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.45. Annualized volatility over the trailing 10 years is 118.08%. Over the trailing twelve months the total return is −9.00%. Measured over 10 years, that is −43.71% a year compounded.

Growth & Income

No dividend is on file for IMUX.

2026 is still running; the total return is +40.07% year to date. The strongest complete calendar year on file is 2020 at +57.63%; the weakest is 2018 at −96.87%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Immunic, Inc. (IMUX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunic, Inc. IMUX $102.06M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immunic, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immunic, Inc.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Visit website →